Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 6,428 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 6,428 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $62.18, for a total value of $399,693.04. Following the transaction, the chief executive officer owned 1,041,667 shares in the company, valued at approximately $64,770,854.06. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
• On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total value of $1,528,250.00.
• On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $58.65, for a total value of $1,466,250.00.
• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.

Liquidia Stock Performance

NASDAQ:LQDA opened at $62.03 on Friday. The firm has a market capitalization of $5.52 billion, a PE ratio of 443.10 and a beta of 0.41. The business’s fifty day moving average price is $44.03 and its 200 day moving average price is $38.31. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $63.46.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. purchased a new stake in Liquidia during the 3rd quarter worth $7,290,000. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter worth about $37,114,000. Apis Capital Advisors LLC bought a new stake in shares of Liquidia in the 3rd quarter worth about $9,569,000. Farallon Capital Management LLC boosted its holdings in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in shares of Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Wells Fargo & Company increased their price target on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Finally, Needham & Company LLC raised their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).